BREAKING: Study suggests immune system's coronavirus-fighting antibodies do not fade quickly, a hopeful sign for vaccine efforts. A report from tests on more than 30,000 people in Iceland show the antibodies last at least four months after diagnosis.
FILE - In this Friday, June 12, 2020 file photo, a woman has blood drawn for COVID-19 antibody testing in Dearborn, Mich. Antibodies that people make to fight coronavirus infection last at least four months and do not fade quickly as some earlier reports suggested -- a good sign that vaccines may be able to give long-lasting immunity, scientists are reporting on Tuesday, Sept. 1, 2020, in the New England Journal of Medicine.
Antibodies that people make to fight the new coronavirus last for at least four months after diagnosis and do not fade quickly, as some earlier reports suggested, scientists have found.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Economist El-Erian says derivatives show retail traders may be drowned by a large correction in stocks | Markets InsiderMohamed El-Erian said in an op-ed in the Financial Times that the boom in retail trading may slow down as the options market is signalling a cor...
Read more »
The University of Oxford is set to begin large trials of its COVID-19 vaccine in the U.S.Despite pressure from the White House, researchers may not be able to say whether the vaccine works until after the election.
Read more »
COVID-19 often goes undiagnosed in hospital workers; virus may impair heart functionsThe following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
Read more »
Explainer: How common cold viruses are being used in vaccines from Russia, ChinaThe modified common cold viruses behind high-profile COVID-19 vaccine candidates from China's CanSino Biologics and Russia's Gamaleya Institute have been studied for decades, but are still not widely used.
Read more »
Third virus vaccine reaches major hurdle: final US testingA handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle — looking for the needed proof that they really work. AstraZeneca announced Monday its vaccine candidate has entered the final testing stage in the U.S. The Cambridge, England-based company
Read more »
AstraZeneca's COVID-19 vaccine candidate begins late-stage U.S. studyAstraZeneca Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate.
Read more »